GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » RTW Biotech Opportunities Ltd (LSE:RTW) » Definitions » Debt-to-Revenue

RTW Biotech Opportunities (LSE:RTW) Debt-to-Revenue : N/A (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is RTW Biotech Opportunities Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

RTW Biotech Opportunities's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. RTW Biotech Opportunities's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. RTW Biotech Opportunities's annualized Revenue for the quarter that ended in Dec. 2024 was $0.00 Mil.


RTW Biotech Opportunities Debt-to-Revenue Historical Data

The historical data trend for RTW Biotech Opportunities's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RTW Biotech Opportunities Debt-to-Revenue Chart

RTW Biotech Opportunities Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial - N/A N/A - -

RTW Biotech Opportunities Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A - - - N/A

Competitive Comparison of RTW Biotech Opportunities's Debt-to-Revenue

For the Asset Management subindustry, RTW Biotech Opportunities's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RTW Biotech Opportunities's Debt-to-Revenue Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, RTW Biotech Opportunities's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where RTW Biotech Opportunities's Debt-to-Revenue falls into.


;
;

RTW Biotech Opportunities Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

RTW Biotech Opportunities's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 38.729
=0.00

RTW Biotech Opportunities's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2024) Revenue data.


RTW Biotech Opportunities Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of RTW Biotech Opportunities's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


RTW Biotech Opportunities Business Description

Traded in Other Exchanges
N/A
Address
St Julian’s Avenue, Royal Chambers, 1st Floor, Saint Peter Port, GGY, GY1 3JX
RTW Biotech Opportunities Ltd is an investment fund focused on identifying transformative assets with growth potential across the life sciences sector. Its approach is driven by applying deep scientific expertise with a long-term investment horizon. Geographically, it operates in U.S. &Canada, UK & EU, and Rest of the world.

RTW Biotech Opportunities Headlines

No Headlines